A Study of Safety and Immunogenicity of a Malaria Vaccine Candidate

NCT00284973 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Prophylaxis Against Plasmodium Falciparum Malaria

Interventions

BIOLOGICAL: Plasmodium falciparum Chimeric Prot. 2.9 - Montanide ISA 720

Sponsor

Shanghai Wanxing Bio-Pharmaceutical Co. Ltd.

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]